Read by QxMD icon Read

Hypoactive sexual desire disorder

Karla Zanolla Dias de Souza, Fabiene Bernardes Castro Vale, Selmo Geber
OBJECTIVE: The objective of this study was to evaluate the efficacy of Tribulus terrestris for the treatment of hypoactive sexual desire disorder in postmenopausal women and evaluate its effect on the serum levels of testosterone. METHODS: We performed a prospective randomized, double-blinded, placebo-controlled study, during 18 months. A total of 45 healthy sexually active postmenopausal women reporting diminished libido were selected to participate in the study and were randomly assigned to receive 750 mg/d of T terrestris or placebo for 120 days...
October 10, 2016: Menopause: the Journal of the North American Menopause Society
Hatta Sidi, Duni Asmidar, Loh Huai Seng, Nik Ruzyanei Nik Jaafar, Marhani Midi, Ng Chong Guan
OBJECTIVES: The current study compares the risk of sexual pain in depressed female patients in remission between those who were treated with Escitalopram and Fluoxetine. The associated factors were also examined. METHODS: This is a cross-sectional study involved 112 depressed female patients (56 treated with Escitalopram and 56 treated with Fluoxetine) who were in remission (as defined by Diagnostic and Statistical Manual-IV (DSM-IV) in the past 2 months and Montgomery-Asberg Depression Rating Scale (MADRS) score of ≤ 10) from the psychiatric clinic, University Kebangsaan Malaysia Medical Centre (UKMMC)...
March 1, 2016: Psychopharmacology Bulletin
C Terrier, J-E Terrier
INTRODUCTION: In August 2015, the US Food and Drug Administration (FDA) has approved Addyi(®) (flibanserin) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in pre-menopausal women. We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug in women with HSDD. PATIENTS AND METHODS: A systematic literature review from the PubMed database search was carried out until April 2016 using the following keywords: "HSDD", "flibanserin", "sexual desire" and "ransomised controlled trial"...
September 20, 2016: Progrès en Urologie
Paige E Tucker, Christobel Saunders, Max K Bulsara, Jason Jit-Sun Tan, Stuart G Salfinger, Helena Green, Paul A Cohen
OBJECTIVES: To investigate the prevalence of sexual dysfunction in women with a history of breast cancer following risk-reducing salpingo-oophorectomy (RRSO). A secondary objective was to examine the effect of a prior diagnosis of breast cancer, and other factors, on sexuality and quality of life (QoL) outcomes. STUDY DESIGN: Cross-sectional study of 119 women who underwent RRSO between 2009 and 2014. MAIN OUTCOME MEASURES: Data were collected via a questionnaire comprising demographic information and validated measures of sexual function, sexual distress, relationship satisfaction, body image, psychological stress, menopause symptoms and general quality of life...
September 1, 2016: Breast: Official Journal of the European Society of Mastology
Allen F Shaughnessy
No abstract text is available yet for this article.
September 1, 2016: American Family Physician
Cheryl B Iglesia
PURPOSE OF REVIEW: The purpose of this review is to describe new terminology for vulvovaginal atrophy and female sexual dysfunction and to highlight recent findings related to vaginal moisturizers, lubricants and prescription estrogen preparations. RECENT FINDINGS: Sexual health is a marker for overall health. A minority (40%) of healthcare providers routinely ask about sexual problems and its impact on quality of life. New terminology by the American Psychiatric Association divides female sexual disorders into three categories: arousal/interest disorder, orgasmic disorder and genital pain and penetration disorder...
October 2016: Current Opinion in Obstetrics & Gynecology
Heidi Collins Fantasia
Female hypoactive sexual desire disorder (HSDD) is one type of sexual problem that can affect women. It is characterized by low or absent sexual desire that cannot be attributed to another cause and results in difficulty in interpersonal relationships. HSDD is not well understood, and women may not report symptoms of difficulties to their health care providers. In August 2015, the U.S. Food and Drug Administration approved flibanserin, a nonhormonal oral medication for the treatment of HSDD in premenopausal women...
June 2016: Nursing for Women's Health
Weronika Chańska, Katarzyna Grunt-Mejer
The current debate around sexual dysfunctions focuses mostly on the pharmacological regulation of lowered sexual desire in women. The Food and Drug Administration approval of the first drug-Addyi-to treat this condition was preceded by a campaign, in which ethically saturated arguments were used to lobby policy makers. This article provides a critical evaluation of these arguments. In particular, we focus our attention on deceitful and unethical use of moral arguments and concepts. First, we present the context in which hypoactive sexual desire disorder is defined as a serious medical condition, showing how non-medical and non-scientific influences shaped the understanding of the problem...
June 8, 2016: Journal of Medical Ethics
Carlos Eduardo Paiva, Fabiana Faria Rezende, Bianca Sakamoto Ribeiro Paiva, Edmundo Carvalho Mauad, Gustavo Zucca-Matthes, Estela Cristina Carneseca, Kari Juhani Syrjänen, Leslie R Schover
Sexual dysfunction is a common and distressing consequence of breast cancer (BC) treatment. In the present study, we investigated the sexual functioning of BC patients and its association with women's personal characteristics and cancer treatments. In this cross-sectional study, sexual function was assessed using the Female Sexual Function Index (FSFI). The health-related quality of life (HRQOL) was measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and its breast module BR-23...
June 3, 2016: Archives of Sexual Behavior
Marjan Anvar Abnavi, Jamshid Ahmadi, Sajedeh Hamidian, Sara Ghaffarpour
BACKGROUND: Opiate abuse in males has significant effects on their sexual functions. In contrast, sexuality in females is a multidimensional issue that can strongly be affected by several factors in their partners. However, only a limited number of studies have assessed the role of males' opioid dependency in their female partners' sexual function. OBJECTIVES: The present study aimed to evaluate the effect of males' opioid dependency on their wives' sexual function compared to the sexual function of the females whose husbands were not opioid dependent...
March 2016: International Journal of High Risk Behaviors & Addiction
Allen D Seftel
No abstract text is available yet for this article.
May 2016: Journal of Urology
Harry Holt, Jeffrey Tingen
No abstract text is available yet for this article.
May 15, 2016: American Family Physician
Jae Hong Sang, Tae-Hee Kim, Soo Ah Kim
There have been several products developed for male sexual dysfunction. However, developing agents for female sexual dysfunction is lagging behind for various reasons. Sildenafil citrate (Viagra) and Tadalafil (Cialis), which have been prescribed for male sexual function disorders, are known to act on vessels.[1] On the other hand, flibanserin is thought to act on brain. Flibanserin has been approved by U. S. Food and Drug Administration (FDA) for treatment of hypoactive sexual desire disorder (HSDD) of premenopausal women in 2015, and is expected to be released in South Korea soon...
April 2016: Journal of Menopausal Medicine
Patrick Meyer
Hypoactive sexual desire disorder (HSDD) is a deficiency of sexual desire that causes marked personal or interpersonal distress. It occurs in approximately 1 in 10 adult women. A number of potential contributory factors (hormonal, neurobiological and psychosocial) have been identified. Testosterone plays an excitatory role in sexual desire but the mechanism is not yet well understood. Treatment with testosterone has been shown to improve sexual desire in menopausal women with HSDD. However, there are limited data concerning premenopausal women and long-term safety...
March 16, 2016: Revue Médicale Suisse
A Alcántara Montero, C I Sánchez Carnerero
Many women will likely experience a sexual problem in their lifetime. Female sexual dysfunction is a broad term used to describe 3 categories of disorders of a multifactorial nature. Effective, but limited pharmacotherapeutic options exist to address female sexual dysfunction. The FDA recently approved the first agent for treatment of hypoactive sexual desire disorder in pre-menopausal women. Off-label use of hormonal therapies, particularly oestrogen and testosterone, are the most widely employed for female sexual dysfunction, particularly in post-menopausal women...
July 2016: Semergen
Susan H Oakley, J Walther-Liu, C C Crisp, R N Pauls
INTRODUCTION: Female sexual dysfunction affects up to 43% of women in the United States and hypoactive sexual desire disorder (HSDD) is the most common type; however, we lack treatment options showing improvement for this condition. AIMS: To investigate whether acupuncture therapy could improve HSDD. METHODS: Premenopausal women with a primary diagnosis of HSDD were included in a single-arm prospective pilot study that was approved by the institutional review board...
September 2016: Sexual Medicine
Susan R Davis, Roisin Worsley, Karen K Miller, Sharon J Parish, Nanette Santoro
INTRODUCTION: Androgens have been implicated as important for female sexual function and dysfunction. AIM: To review the role of androgens in the physiology and pathophysiology of female sexual functioning and the evidence for efficacy of androgen therapy for female sexual dysfunction (FSD). METHODS: We searched the literature using online databases for studies pertaining to androgens and female sexual function. Major reviews were included and their findings were summarized to avoid replicating their content...
February 2016: Journal of Sexual Medicine
Loes Jaspers, Frederik Feys, Wichor M Bramer, Oscar H Franco, Peter Leusink, Ellen T M Laan
IMPORTANCE: In August 2015, the US Food and Drug Administration (FDA) approved flibanserin as a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, despite concern about suboptimal risk-benefit trade-offs. OBJECTIVE: To conduct a systematic review and meta-analysis of randomized clinical trials assessing efficacy and safety of flibanserin for the treatment of HSDD in women. DATA SOURCES: Medical databases (among others, Embase, Medline, Psycinfo) and trial registries were searched from inception to June 17, 2015...
April 2016: JAMA Internal Medicine
Mina Malary, Soghra Khani, Mehdi Pourasghar, Mahmood Moosazadeh, Zeinab Hamzehgardeshi
BACKGROUND: As a mental response to sexual stimuli, sexual desire determines human sexual behavior and represents the cognitive capacity of sexual stimulation, so that avoiding sexual activity has a very negative effect on the discharge of intimacy and joy in couple's relationship and threatens the stability relationship, which can finally end in sexual dissatisfaction and divorce; it may even affect the reproduction. This study, reviews the literature on biopsychosocial determinants of hypoactive sexual desire disorder in women in childbearing ages...
December 2015: Materia Socio-medica
Ximena Vallejos, Christine Wu
OBJECTIVE: To review pivotal clinical trials, pharmacology, contraindications, precautions, and key patient education points of flibanserin for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. DATA SOURCES: A literature search of PubMed using the key words flibanserin and HSDD was conducted in September 2015. There was no time frame to exclude relevant clinical trials. All trials referenced were published between March 2012 and June 2014...
February 11, 2016: Journal of Pharmacy Practice
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"